GEN Exclusives

More »

GEN News Highlights

More »
May 13, 2008

Bristol-Myers Squibb Pays $25M Upfront to Help Advance KAI’s Cardiovascular Candidate

  • Bristol-Myers Squibb inked an agreement for the development and commercialization of KAI Pharmaceuticals’ inhibitor of the delta protein kinase C pathway, KAI-9803, which is designed to reduce the size of the heart attack and to improve clinical outcomes during treatment of acute myocardial infarction. KAI-9803 is expected to enter Phase IIb testing by the end of 2008 in patients with ST elevation myocardial infarction.

    KAI will receive an upfront cash payment of $25 million. Bristol-Myers Squibb will fund all future development including the Phase IIb trial to be conducted by KAI. In addition, at KAI’s option, Bristol-Myers Squibb will purchase $10 million of KAI stock at the time of a qualified IPO or under other specified future conditions.

    KAI may receive from Bristol-Myers Squibb up to $192 million in milestone payments based on the achievement of prespecified development and regulatory milestones for KAI-9803. KAI could be eligible for additional milestones if other compounds are developed. The company will also have an option to copromote KAI-9803 in the U.S. and will receive royalty payments on the products net sales worldwide.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?